CPIX vs. ASMB, LLY, JNJ, ABBV, MRK, PFE, BMY, ZTS, RPRX, and CORT
Should you be buying Cumberland Pharmaceuticals stock or one of its competitors? The main competitors of Cumberland Pharmaceuticals include Assembly Biosciences (ASMB), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), and Corcept Therapeutics (CORT). These companies are all part of the "pharmaceuticals" industry.
Cumberland Pharmaceuticals vs. Its Competitors
Cumberland Pharmaceuticals (NASDAQ:CPIX) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.
In the previous week, Assembly Biosciences had 3 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 8 mentions for Assembly Biosciences and 5 mentions for Cumberland Pharmaceuticals. Cumberland Pharmaceuticals' average media sentiment score of 0.69 beat Assembly Biosciences' score of 0.48 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the media.
15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are held by institutional investors. 44.9% of Cumberland Pharmaceuticals shares are held by company insiders. Comparatively, 5.1% of Assembly Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Cumberland Pharmaceuticals has a beta of -0.41, meaning that its share price is 141% less volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.
Assembly Biosciences has a consensus price target of $41.25, indicating a potential upside of 49.13%. Given Assembly Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Assembly Biosciences is more favorable than Cumberland Pharmaceuticals.
Cumberland Pharmaceuticals has higher revenue and earnings than Assembly Biosciences. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.
Cumberland Pharmaceuticals has a net margin of -6.97% compared to Assembly Biosciences' net margin of -117.20%. Cumberland Pharmaceuticals' return on equity of 7.48% beat Assembly Biosciences' return on equity.
Summary
Cumberland Pharmaceuticals and Assembly Biosciences tied by winning 8 of the 16 factors compared between the two stocks.
Get Cumberland Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CPIX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cumberland Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CPIX) was last updated on 10/14/2025 by MarketBeat.com Staff
